…IRA, and by other healthcare legislative reforms that may be enacted or adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
All entries for: Oncology
May 1, 2025
Bicycle Therapeutics
Negative Outlook
Cambridge, MA
201-500 employees
Disease Area: Cardiology, Multiple, Neurological Diseases, Oncology
Drug Type: Small Molecule
May 1, 2025
Abpro Holdings
Neutral Outlook
Woburn, MA
1-50 employees
The outcomes of these challenges on the IRA, and the effect of the IRA on our business and the healthcare industry in general, are not yet known.
Disease Area: Immune Diseases, Infectious Diseases, Multiple, Oncology
Drug Type: Biologic
May 1, 2025
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.
Disease Area: Cardiology, Chronic Disease, Immune Diseases, Metabolic Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
April 30, 2025
ImmunityBio - San Diego
Negative Outlook
San Diego, CA
501-1,000 employees
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be timeintensive and expensive, resulting in a material adverse effect on our business.
Disease Area: Infectious Diseases, Multiple, Oncology
Drug Type: Biologic
April 30, 2025
Iovance Biotherapeutics
Negative Outlook
San Carlos, CA
501-1,000 employees
We continue to evaluate what effect, if any, the IRA may have on our business. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
Disease Area: Oncology
Drug Type: Biologic
April 30, 2025
Zentalis Pharmaceuticals
Neutral Outlook
San Diego, CA
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Oncology
Drug Type: Small Molecule
April 30, 2025
GSK - Philadelphia
Negative Outlook
Philadelphia, PA
50,001+ employees
“HIV: HIV sales grew by 7% this quarter with the US growing at 9%. This was driven by a 9 percentage point increase in patient demand from Cabenuva, Apretude and Dovato reflecting strong market share growth. Growth in the quarter also benefited from customer ordering patterns, offset by unfavourable price impacts from channel mix adjustments and the impact of IRA Medicare Part D redesign. Nucala: Sales growth in the quarter was driven by strong performance across all regions, reflecting higher patient demand for treatments addressing eosinophilic-led disease. Growth in the quarter in the US was predominantly driven by the impacts of channel inventory reductions occurring in 2024, with further underlying double digit volume increases being largely offset by unfavourable price impacts, including the impact of IRA Medicare Part D redesign.
Trelegy: Trelegy sales continued to grow in the quarter, with strong volume growth continued across all regions reflecting patient demand, SITT class growth, and increased market share. Specifically in the US, continued strong volume growth is partially offset by price unfavourability resulting from channel mix and pricing pressures and the impact of IRA Medicare Part D redesign. US performance in the quarter reflected the introduction of the IRA Medicare Part D redesign, which adversely impacted a number of products across Specialty Medicines, Vaccines and General Medicines.”
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Small Molecule
April 29, 2025
Terns Pharmaceutical
Negative Outlook
Foster City, CA
51-200 employees
Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
April 29, 2025
Incyte Corp
Negative Outlook
Wilmington, DE
1,001-5,000 employees
We expect our sales allowances to fluctuate from quarter to quarter due to changes in the volume of purchases eligible for government mandated discounts and rebates as well as changes in discount percentages, which are impacted by potential future price increases, rate of inflation, and other factors, such as changes to the 340B drug pricing program. In 2025, we expect to see a reduction in our sales allowances owed under Medicare Part D, due to changes from the Inflation Reduction Act, which effective January 1, 2025, replaced the manufacturer’s coverage gap liability with a different discount structure.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
April 29, 2025
OmniAb
Neutral Outlook
Emeryville, CA
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic